Novavax

Novavax

Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

$1.8B

Market Cap • 9/25/2026

1987

(39 years)

Founded

1995

(31 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

4,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

1,8B

EV

1,3B

EV/Revenue

3,2

EV/EBITDA

-6,2

EV/EBIT

-5,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,3%

Total Yield

0,3%

Payout

0%

Retained Earnings

-4,6B

Profitability

Gross Margin

78,6%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

82,2%

Capex/Revenue

1,8%

Capex/D&A

41,6%

Capex/OCF

-20,1%

SBC/OCF

—

% PPE

6,1%

% Goodwill

11,8%

ROE

323,7%

ROIC

—

Growth

CAGR Revenue 5Y

-18,9%

CAGR Op. Income 5Y

-24,1%

CAGR Net Income 5Y

-23,6%

CAGR EPS 5Y

-35,8%

Leverage

N.D./EBITDA

2

Debt/Equity

0%

Current Ratio

2,3

Quick Ratio

2,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium